Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Labianca

Showing results (151-160 of 174) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2012
Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trialAndrea Ardizzoni, Marcello Tiseo, Luca Boni, et al.
Journal of Thrombosis and Haemostasis : JTH|May 13, 2020
Thrombin generation predicts early recurrence in breast cancer patientsMarina Marchetti, Cinzia Giaccherini, Giovanna Masci, et al.
European Journal of Cancer (Oxford, England : 1990)|March 21, 2021
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trialGerardo Rosati, Sara Lonardi, Fabio Galli, et al.
JAMA Oncology|October 2, 2025
The Definition of Cure in Colon Cancer: A Pooled Analysis of 15 Randomized Clinical TrialsAlessandro Pastorino, Heshan Liu, Levi Pederson, et al.
Scientific Reports|August 10, 2019
Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant ChemotherapyAnnamaria Ruzzo, Francesco Graziano, Francesca Galli, et al.
Scientific Reports|February 2, 2020
Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant ChemotherapyAnnamaria Ruzzo, Francesco Graziano, Francesca Galli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2022
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant TrialsClaire Gallois, Qian Shi, Jeffrey P Meyers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2024
Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 TrialsClaire Gallois, Qian Shi, Levi D Pederson, et al.
Scientific Reports|November 6, 2014
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patientsAnnamaria Ruzzo, Francesco Graziano, Fabio Galli, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 10, 2015
Assessment of a HER2 scoring system for colorectal cancer: results from a validation studyEmanuele Valtorta, Cosimo Martino, Andrea Sartore-Bianchi, et al.
Pageof 18

Showing results (151-160 of 174) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2012
Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trialAndrea Ardizzoni, Marcello Tiseo, Luca Boni, et al.
Journal of Thrombosis and Haemostasis : JTH|May 13, 2020
Thrombin generation predicts early recurrence in breast cancer patientsMarina Marchetti, Cinzia Giaccherini, Giovanna Masci, et al.
European Journal of Cancer (Oxford, England : 1990)|March 21, 2021
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trialGerardo Rosati, Sara Lonardi, Fabio Galli, et al.
JAMA Oncology|October 2, 2025
The Definition of Cure in Colon Cancer: A Pooled Analysis of 15 Randomized Clinical TrialsAlessandro Pastorino, Heshan Liu, Levi Pederson, et al.
Scientific Reports|August 10, 2019
Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant ChemotherapyAnnamaria Ruzzo, Francesco Graziano, Francesca Galli, et al.
Scientific Reports|February 2, 2020
Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant ChemotherapyAnnamaria Ruzzo, Francesco Graziano, Francesca Galli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2022
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant TrialsClaire Gallois, Qian Shi, Jeffrey P Meyers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2024
Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 TrialsClaire Gallois, Qian Shi, Levi D Pederson, et al.
Scientific Reports|November 6, 2014
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patientsAnnamaria Ruzzo, Francesco Graziano, Fabio Galli, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 10, 2015
Assessment of a HER2 scoring system for colorectal cancer: results from a validation studyEmanuele Valtorta, Cosimo Martino, Andrea Sartore-Bianchi, et al.
Pageof 18